Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: A systematic review of monoclonal antibodies and fusion proteins in combination strategies

The systematic review synthesized evidence on CD47-targeted combinations for hematologic malignancies. Preliminary data on multiple myeloma showed encouraging activity in triple-class refractory diseases. While other malignancies like high-risk MDS/AML and lymphomas demonstrated high response rates, the CD47 blockade remains investigational. These combinations generally exhibit manageable safety profiles, mainly involving anemia. However, recent phase III trials have not yet confirmed the broad clinical benefit.